Scienture Holdings, Inc. (SCNX): R&D Expense
$1.96M
Year ended 2025-12-31
$2.50M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.96M | -12.5% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $2.24M | n/a | 2026-03-30, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | 2025-12-31 | $1.96M | -12.5% |
| Medicinova Inc (MNOV) | 2025-12-31 | $6.70M | -1.5% |
| Can-Fite BioPharma Ltd. (CANF) | 2025-12-31 | $6.69M | +16.3% |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | $17.77M | -15.1% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
| Quantum Cyber N.V. (QUCY) | 2025-12-31 | $4.91M | -14.2% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $67.75M | -0.2% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
Compare SCNX, MNOV, CANF, MREO side by side · Screen every company in Pharmaceutical Preparations ↗